Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

During the last 10 years, the multikinase inhibitor sorafenib has emerged as the only systemic treatment for unresectable hepatocellular carcinoma (HCC). More recently, data from the Phase III REFLECT trial showed that another multikinase inhibitor, namely, lenvatinib, was non-inferior to sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Personeni, Nicola, Pressiani, Tiziana, Rimassa, Lorenza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362912/
https://www.ncbi.nlm.nih.gov/pubmed/30775342
http://dx.doi.org/10.2147/JHC.S168953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362912/
https://www.ncbi.nlm.nih.gov/pubmed/30775342
http://dx.doi.org/10.2147/JHC.S168953

Ejemplares similares